PBIGF (Paradigm Biopharmaceuticals) Accounts Payable : $0.37 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Accounts Payable?

Paradigm Biopharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2024 was $0.37 Mil.

Paradigm Biopharmaceuticals's quarterly Accounts Payable declined from Dec. 2023 ($6.68 Mil) to Jun. 2024 ($1.87 Mil) and declined from Jun. 2024 ($1.87 Mil) to Dec. 2024 ($0.37 Mil).

Paradigm Biopharmaceuticals's annual Accounts Payable increased from Jun. 2022 ($4.98 Mil) to Jun. 2023 ($8.16 Mil) but then declined from Jun. 2023 ($8.16 Mil) to Jun. 2024 ($1.87 Mil).

Paradigm Biopharmaceuticals Accounts Payable Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Accounts Payable Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Accounts Payable

Get a 7-Day Free Trial

1.90

3.81

4.98

8.16

1.87

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable	Get a 7-Day Free Trial														9.22	8.16	6.68	1.87	0.37

Paradigm Biopharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Paradigm Biopharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

P86:Germany PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.